Isoproterenol Hydrochloride

ISOPROTERENOL HYDROCHLORIDE- isoproterenol hydrochloride injection, solution
Amring Pharmaceuticals Inc.

Isoproterenol Hydrochloride Injection, USP Rx only Sterile Injection

DESCRIPTION

Isoproterenol Hydrochloride, USP is 3,4-Dihydroxy-α-[(isopropylamino)methyl] Benzyl alcohol Hydrochloride, a synthetic sympathomimetic amine that is structurally related to epinephrine but acts almost exclusively on beta receptors. The molecular formula is C11 H17 NO3 • HCl. It has a molecular weight of 247.72 and the following structural formula:

Isoproterenol Hydrochloride, USP is a racemic compound.

Structural Formula
(click image for full-size original)

Each milliliter of the sterile solution contains:

Isoproterenol Hydrochloride, USP0.2 mg
Edetate Disodium (EDTA)0.2 mg
Sodium Chloride7.0 mg
Sodium Citrate, Dihydrate2.07 mg
Citric Acid, Anhydrous2.5 mg
Water for Injection1.0 mL

The pH is adjusted between 2.5 and 4.5 with Hydrochloric acid or Sodium Hydroxide.

The sterile solution is nonpyrogenic and can be administered by the intravenous, intramuscular, subcutaneous, or intracardiac routes.

CLINICAL PHARMACOLOGY

Isoproterenol is a potent nonselective beta-adrenergic agonist with very low affinity for alpha-adrenergic receptors. Intravenous infusion of Isoproterenol in man lowers peripheral vascular resistance, primarily in skeletal muscle but also in renal and mesenteric vascular beds. Diastolic pressure falls. Renal blood flow is decreased in normotensive subjects but is increased markedly in shock. Systolic blood pressure may remain unchanged or rise, although mean arterial pressure typically falls. Cardiac output is increased because of the positive inotropic and chronotropic effects of the drug in the face of diminished peripheral vascular resistance. The cardiac effects of Isoproterenol may lead to palpitations, sinus tachycardia, and more serious arrhythmias; large doses of Isoproterenol may cause myocardial necrosis in animals.

Isoproterenol relaxes almost all varieties of smooth muscle when the tone is high, but this action is most pronounced on bronchial and gastrointestinal smooth muscle. It prevents or relieves bronchoconstriction, but tolerance to this effect develops with overuse of the drug.

In man, Isoproterenol causes less hyperglycemia than does epinephrine. Isoproterenol and epinephrine are equally effective in stimulating the release of free fatty acids and energy production.

Absorption, Fate, and Excretion. Isoproterenol is metabolized primarily in the liver and other tissues by COMT. Isoproterenol is a relatively poor substrate for MAO and is not taken up by sympathetic neurons to the same extent as are epinephrine and norepinephrine. The duration of action of Isoproterenol may therefore be longer than that of epinephrine, but is still brief.

INDICATIONS AND USAGE

Isoproterenol Hydrochloride Injection, USP is indicated:

  • For mild or transient episodes of heart block that do not require electric shock or pacemaker therapy.
  • For serious episodes of heart block and Adams-Stokes attacks (except when caused by ventricular tachycardia or fibrillation) (See CONTRAINDICATIONS).
  • For use in cardiac arrest until electric shock or pacemaker therapy, the treatments of choice, is available (See CONTRAINDICATIONS).
  • For bronchospasm occurring during anesthesia.
  • As an adjunct to fluid and electrolyte replacement therapy and the use of other drugs and procedures in the treatment of hypovolemic and septic shock, low cardiac output (hypoperfusion) states, congestive heart failure, and cardiogenic shock (See WARNINGS).

CONTRAINDICATIONS

Use of Isoproterenol Hydrochloride Injection is contraindicated in patients with tachyarrhythmias; tachycardia or heart block caused by digitalis intoxication; ventricular arrhythmias which require inotropic therapy; and angina pectoris.

WARNINGS

Isoproterenol Hydrochloride Injection, by increasing myocardial oxygen requirements while decreasing effective coronary perfusion, may have a deleterious effect on the injured or failing heart. Most experts discourage its use as the initial agent in treating cardiogenic shock following myocardial infarction.

However, when a low arterial pressure has been elevated by other means, Isoproterenol Hydrochloride Injection may produce beneficial hemodynamic and metabolic effects.

In a few patients, presumably with organic disease of the AV node and its branches, Isoproterenol Hydrochloride Injection has paradoxically been reported to worsen heart block or to precipitate Adams-Stokes attacks during normal sinus rhythm or transient heart block.

PRECAUTIONS

General

Isoproterenol Hydrochloride Injection should generally be started at the lowest recommended dose. This may be gradually increased if necessary while carefully monitoring the patient. Doses sufficient to increase the heart rate to more than 130 beats per minute may increase the likelihood of inducing ventricular arrhythmias. Such increases in heart rate will also tend to increase cardiac work and oxygen requirements which may adversely affect the failing heart or the heart with a significant degree of arteriosclerosis.

Adequate filling of the intravascular compartment by suitable volume expanders is of primary importance in most cases of shock and should precede the administration of vasoactive drugs. In patients with normal cardiac function, determination of central venous pressure is a reliable guide during volume replacement. If evidence of hypo perfusion persists after adequate volume replacement, Isoproterenol Hydrochloride Injection may be given.

In addition to the routine monitoring of systemic blood pressure, heart rate, urine flow, and the electrocardiograph, monitor the response to therapy by frequent determination of the central venous pressure and blood gases. Closely observe patients in shock during Isoproterenol Hydrochloride Injection administration. If the heart rate exceeds 110 beats per minute, it may be advisable to decrease the infusion rate or temporarily discontinue the infusion. Determinations of cardiac output and circulation time may also be helpful. Take appropriate measures to ensure adequate ventilation. Pay attention to acid-base balance and to the correction of electrolyte disturbances.

Drug Interactions

Isoproterenol Hydrochloride Injection and epinephrine should not be administered simultaneously because both drugs are direct cardiac stimulants and their combined effects may induce serious arrhythmias. The drugs may, however, be administered alternately provided a proper interval has elapsed between doses.

Avoid Isoproterenol Hydrochloride when potent inhalational anesthetics such as halothane are employed because of potential to sensitize the myocardium to effects of sympathomimetic amines.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Long-term studies in animals to evaluate the carcinogenic potential of Isoproterenol Hydrochloride have not been done. Mutagenic potential and effect on fertility have not been determined. There is no evidence from human experience that Isoproterenol Hydrochloride Injection may be carcinogenic or mutagenic or that it impairs fertility.

Pregnancy

Animal reproduction studies have not been conducted with Isoproterenol Hydrochloride. It is also not known whether Isoproterenol Hydrochloride can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Isoproterenol Hydrochloride should be given to a pregnant woman only if clearly needed.

Nursing Mothers

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Isoproterenol Hydrochloride Injection is administered to a nursing woman.

Pediatric Use

Safety and efficacy of Isoproterenol in pediatric patients have not been established.

Intravenous infusions of Isoproterenol in refractory asthmatic children at rates of 0.05 to 2.7 mcg/kg/min have caused clinical deterioration, myocardial necrosis, congestive heart failure and death. The risks of cardiac toxicity appear to be increased by some factors [acidosis, hypoxemia, co-administration of corticosteroids, co-administration of methylxanthines (theophylline, theobromine) or aminophylline] that are especially likely to be present in these patients. If I.V. Isoproterenol is used in children with refractory asthma, patient monitoring must include continuous assessment of vital signs, frequent electrocardiography, and daily measurements of cardiac enzymes, including CPK-MB.

Page 1 of 3 1 2 3

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2024. All Rights Reserved.